JP2023534779A5 - - Google Patents

Info

Publication number
JP2023534779A5
JP2023534779A5 JP2022556575A JP2022556575A JP2023534779A5 JP 2023534779 A5 JP2023534779 A5 JP 2023534779A5 JP 2022556575 A JP2022556575 A JP 2022556575A JP 2022556575 A JP2022556575 A JP 2022556575A JP 2023534779 A5 JP2023534779 A5 JP 2023534779A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
ceramide
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022556575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534779A (ja
JP7809067B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/022914 external-priority patent/WO2021188770A1/en
Publication of JP2023534779A publication Critical patent/JP2023534779A/ja
Publication of JP2023534779A5 publication Critical patent/JP2023534779A5/ja
Application granted granted Critical
Publication of JP7809067B2 publication Critical patent/JP7809067B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022556575A 2020-03-18 2021-03-18 抗セラミド抗体 Active JP7809067B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062991232P 2020-03-18 2020-03-18
US62/991,232 2020-03-18
PCT/US2021/022914 WO2021188770A1 (en) 2020-03-18 2021-03-18 Anti-ceramide antibodies

Publications (3)

Publication Number Publication Date
JP2023534779A JP2023534779A (ja) 2023-08-14
JP2023534779A5 true JP2023534779A5 (enExample) 2024-04-01
JP7809067B2 JP7809067B2 (ja) 2026-01-30

Family

ID=77771401

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022556575A Active JP7809067B2 (ja) 2020-03-18 2021-03-18 抗セラミド抗体

Country Status (11)

Country Link
US (1) US20230167197A1 (enExample)
EP (1) EP4121110A4 (enExample)
JP (1) JP7809067B2 (enExample)
KR (1) KR20230031814A (enExample)
CN (1) CN115811987A (enExample)
AU (1) AU2021236669A1 (enExample)
BR (1) BR112022018682A2 (enExample)
CA (1) CA3172201A1 (enExample)
IL (1) IL296550A (enExample)
MX (1) MX2022011591A (enExample)
WO (1) WO2021188770A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022883A1 (en) 2014-08-07 2016-02-11 Memorial Sloan-Kettering Cancer Center Anti-ceramide antibodies
EP4308231A4 (en) * 2021-03-16 2025-01-29 Memorial Sloan Kettering Cancer Center IMPROVING WOUND HEALING WITH ANTI-CERAMIDE ANTIBODIES

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
EP2289550A3 (en) 2000-01-27 2012-02-15 MedImmune, LLC Ultra high affinity neutralizing antibodies
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EA201170357A1 (ru) * 2008-08-20 2012-05-30 Сентокор Орто Байотек Инк. Инженерные антитела к il-13: композиции, способы и применение
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
US9833949B2 (en) 2011-08-29 2017-12-05 Impossible Objects, Inc. Apparatus for fabricating three-dimensional printed composites
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
WO2016022883A1 (en) 2014-08-07 2016-02-11 Memorial Sloan-Kettering Cancer Center Anti-ceramide antibodies
TWI632160B (zh) * 2015-01-16 2018-08-11 中央研究院 具有標的部分及效應部分的分子構建體
CN118948892A (zh) * 2017-05-01 2024-11-15 朱诺治疗学股份有限公司 细胞疗法与免疫调节化合物的组合
WO2019237035A1 (en) * 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2

Similar Documents

Publication Publication Date Title
CN110536903A (zh) 抗ox40抗体及其用途
RU2019141289A (ru) АНТИ-SIRPα АНТИТЕЛА
JP2020528768A5 (enExample)
RU2014151788A (ru) Молекула, специфически связывающаяся с rsv
RU2012112829A (ru) Анти-gitr-антитела
JP2021520825A5 (enExample)
RU2014122990A (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
RU2019140602A (ru) АНТИ-GARP-TGF-β-АНТИТЕЛА
RU2013110874A (ru) Антитела против il-18r1 и их применения
RU2012112340A (ru) Гуманизированные моноклональные антитела к сеа с созревшей аффинностью
RU2013125459A (ru) АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met
JP2012532851A5 (enExample)
US11851460B2 (en) PD1 binding agents
JP2024542194A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2015504421A5 (enExample)
RU2012103212A (ru) Tlr3 связывающие агенты
JP5780595B2 (ja) 抗緑膿菌作用を有するヒト化PcrV抗体
JP2020515277A5 (enExample)
JP2024520188A5 (enExample)
JP2024516595A5 (enExample)
JP2021511387A5 (enExample)
JP2023510982A5 (enExample)
JP2024540148A5 (enExample)